Altris AI
- 15/12/2022
- Unknown
- $1,000,000
Glaucoma and Age-related macular degeneration (AMD) are the main causes of irreversible blindness worldwide. Correct diagnosis at early stages of these diseases can significantly help ophthalmologists to prescribe appropriate treatment and thereby slow the progress of the disease and prevent significant vision loss.
We are developing a software (AI platform), designed to improve the diagnostic process in ophthalmology by creating a deep learning trained algorithm for automated detection at early, asymptomatic stages of Glaucoma, Age-related macular degeneration (AMD) and other retinal diseases on OCT (optical coherence tomography) images by learning from a large dataset of clinical cases.
Our goal is to develop state-of- the-art ophthalmology diagnosis real-time support platform with extension in many products such as mobile application, smart glasses, web platform and enterprise system.
We build our products to help doctors leverage artificial intelligence, big data, augmented and mixed reality technologies in their daily activities. Our platform and products are bridging the gap in human-machine interaction in ophthalmology and retinal diagnostic.
- Industry Software Development
- Website https://www.altris.ai/
- LinkedIn https://www.linkedin.com/company/altris-ai/
Related People
Andrey Kuropyatnyk, MBAFounder
Altris AI is the SaaS that improves the diagnostic process in ophthalmology by automating the detection of more than 100 pathologies on OCT images. The system is based on the biggest dataset of clinical cases.
Altris AI is an official partner of Topcon Healthcare capable to work with all OCT devices on the market.